Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases

被引：24
|
作者：
Fordy, C [1 ]
Glover, C [1 ]
Davies, MM [1 ]
Allen-Mersh, TG [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sch Med, Dept Gastrointestinal Surg, London, England
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷 / 08期
关键词：
colorectal liver metastases; chemotherapy; fluorouracil resistance; hepatic arterial floxuridine;
D O I：
10.1038/bjc.1998.627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.
引用
收藏
页码：1058 / 1060
页数：3
相关论文
共 50 条
  • [31] REGIONAL CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES - A PHASE-II EVALUATION OF TARGETED HEPATIC ARTERIAL 5-FLUOROURACIL FOR COLORECTAL LIVER METASTASES
    GOLDBERG, JA
    KERR, DJ
    WILMOTT, N
    MCKILLOP, JH
    MCARDLE, CS
    BRITISH JOURNAL OF SURGERY, 1990, 77 (11) : 1238 - 1240
  • [32] A Modified Floxuridine Reduced-Dose Protocol for Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
    Schwantes, Issac R.
    Patel, Ranish K.
    Kardosh, Adel
    Paxton, Jillian
    Eil, Robert
    Chen, Emerson Y.
    Rocha, Flavio G.
    Latour, Emile
    Pegna, Guillaume
    Lopez, Charles D.
    Mayo, Skye C.
    ANNALS OF SURGICAL ONCOLOGY, 2024, : 6537 - 6545
  • [33] Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer? Response
    Kemeny, NE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 2106 - 2106
  • [34] Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
    Kemeny, N.
    Capanu, M.
    D'Angelica, M.
    Jarnagin, W.
    Haviland, D.
    Dematteo, R.
    Fong, Y.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1236 - 1241
  • [35] RANDOMIZED TRIAL OF HEPATIC ARTERIAL FLOXURIDINE, MITOMYCIN, AND CARMUSTINE VERSUS FLOXURIDINE ALONE IN PREVIOUSLY TREATED PATIENTS WITH LIVER METASTASES FROM COLORECTAL-CANCER
    KEMENY, N
    COHEN, A
    SEITER, K
    CONTI, JA
    SIGURDSON, ER
    TAO, Y
    NIEDZWIECKI, D
    BOTET, J
    BUDD, A
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 330 - 335
  • [36] Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer
    Aldrighetti, L
    Arru, M
    Ronzoni, M
    Salvioni, M
    Villa, E
    Ferla, G
    HEPATO-GASTROENTEROLOGY, 2001, 48 (41) : 1302 - 1307
  • [37] Second-line systemic therapy for metastatic colorectal cancer
    Mocellin, Simone
    Baretta, Zora
    Roque i Figuls, Marta
    Sola, Ivan
    Martin-Richard, Marta
    Hallum, Sara
    Cosp, Xavier Bonfill
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01):
  • [38] Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin
    Goere, D., Sr.
    Dsehais, I.
    de Baere, T.
    Boige, V.
    Malka, D.
    Bonnet, S.
    Dromain, C.
    Elias, D.
    Ducreux, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver
    Alberts, S.
    Mahoney, M. R.
    Donohue, J. H.
    Roh, M. S.
    Green, E. M.
    Sargent, D. J.
    Wagman, L. D.
    Bolton, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] 5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer
    Meyer, L
    Hildebrandt, B
    Riess, H
    ONCOLOGY, 2003, 64 (04) : 473 - 474
12345